Ep56: Tim Springer

Episode Summary

Executive Summary: Tim Springer reflects on a career that moved from foundational immunology to transformative biotech entrepreneurship. He describes discovering integrins and leukocyte adhesion molecules, linking basic protein conformational changes to immune function, and translating those insights into drugs and companies including Leukocyte, Scholar Rock, Morphic, and early Moderna. The conversation traces how science, timing, and selective risk-taking shaped major therapeutic advances and his ongoing philanthropic work in protein science.

Main Topics: Early life, family, and formative years: Springer grew up in California in a service-oriented medical family, attended public schools, and entered Yale during the Vietnam era, where political disillusionment briefly pulled him away from science. VISTA and social impact before science: He took a year with VISTA on the Yomba Shoshone Reservation, where he worked on community development, education access, and infrastructure, an experience that showed him the real-world value of public service. Return to science and entry into immunology: After exploring anthropology, sociology, psychology, and physics at Berkeley, Springer settled on biochemistry and pursued graduate work at Harvard, where protein structure, immune recognition, and cell surface biology became central interests. Discovery of integrins and leukocyte adhesion biology: Springer’s core scientific contribution was identifying adhesion molecules such as LFA-1, LFA-2, LFA-3, and later integrins, revealing multistep leukocyte homing and the conformational basis of cell adhesion in immunity. From basic biology to drug development and Leukocyte: Seeing that specific adhesion pathways could be selectively blocked for tissue- or cell-type-specific therapy, Springer founded Leukocyte to translate integrin biology into treatments for autoimmune disease. Long-horizon therapeutic success: vetalizumab/Entyvio: The interview highlights how early work on alpha-4 beta-7 integrin informed vetalizumab (Entyvio), which took years to mature but became a blockbuster for ulcerative colitis and Crohn’s disease. Later entrepreneurship, investing, and philanthropy: Springer went on to help found or support companies such as Scholar Rock, Morphic, Editas, and Moderna, while also founding the Institute for Protein Innovation to strengthen protein science and open biology.

Key Arguments: Basic biology can take decades to reveal its clinical value; Springer’s early adhesion-molecule work later enabled major autoimmune therapies. Protein conformational change is central to function, not just sequence or expression level; integrin activation can dramatically alter ligand affinity. Selective targeting of leukocyte trafficking can provide tissue-specific and cell-type-specific immunomodulation, improving therapeutic precision. Entrepreneurship was necessary because the broader scientific and therapeutic space was too large for one academic lab to pursue alone. Long-term investing and company-building can be a natural extension of scientific insight when paired with timing, collaborators, and willingness to take calculated risks. Open, shared resources for protein science are important because protein biology remains less funded and less visible than nucleic-acid biology.

Data Points: Birth year: 1948 - Springer identifies himself as part of the baby boom generation. Harvard Medical School faculty start: 1977 - He returned to Harvard as faculty after his PhD and postdoc work. Leukocyte founding year: 1993 - Springer says he started Leukocyte to pursue translational integrin biology. First major Leukocyte paper on alpha-4 beta-7 antibody: 1995 - He notes publication of an early paper showing efficacy in a cotton-top marmoset ulcerative colitis model. Leukocyte acquisition value: $600+ million - The company was acquired by Millennium Pharmaceuticals in the late 1990s. Founder-share proceeds: about $100 million - Springer says he received roughly this amount when he sold half his shares. Integrin ligand-affinity increase after conformational change: 4,000-fold and 700-fold - He cites these examples to show how conformational activation changes integrin behavior. VISTA assignment duration: 1 year - He joined VISTA, a one-year domestic service program, before returning to academics. Yale attendance: 1966 to 1967 - He describes his freshman year at Yale during the Vietnam War era. Age at reservation service: 19 - He says the reservation experience was formative for him as a young adult.

Pivotal Quotes: "the Springers have to be smart" — Tim Springer: He recalls his parents’ expectation setting in childhood. "we could block the area code for the skin without interfering with the area code to the gut" — Tim Springer: He explains how leukocyte trafficking biology suggested tissue-selective therapies. "It reveals the inner strength of the rock" — Tim Springer: He connects scholar rocks and protein structure, explaining both the name and his scientific imagination.

Implications: Springer’s story shows how foundational receptor biology can become blockbuster medicine years later. For biotech, it underscores the value of patience, structural insight, and translational entrepreneurship in turning deep science into durable therapies.